Related Experiment Video
Updated: Oct 7, 2025

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment
Antonio F Pardiñas1, Sophie E Smart1,2, Isabella R Willcocks1
1MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Importance:
About 20% to 30% of people with schizophrenia have psychotic symptoms that do not respond adequately to first-line antipsychotic treatment. This clinical presentation, chronic and highly disabling, is known as treatment-resistant schizophrenia (TRS). The causes of treatment resistance and their relationships with causes underlying schizophrenia are largely unknown. Adequately powered genetic studies of TRS are scarce because of the difficulty in collecting data from well-characterized TRS cohorts.
Objective:
To examine the genetic architecture of TRS through the reassessment of genetic data from schizophrenia studies and its validation in carefully ascertained clinical samples.
Design, Setting, And Participants:
Two case-control genome-wide association studies (GWASs) of schizophrenia were performed in which the case samples were defined as individuals with TRS (n = 10 501) and individuals with non-TRS (n = 20 325). The differences in effect sizes for allelic associations were then determined between both studies, the reasoning being such differences reflect treatment resistance instead of schizophrenia. Genotype data were retrieved from the CLOZUK and Psychiatric Genomics Consortium (PGC) schizophrenia studies. The output was validated using polygenic risk score (PRS) profiling of 2 independent schizophrenia cohorts with TRS and non-TRS: a prevalence sample with 817 individuals (Cardiff Cognition in Schizophrenia [CardiffCOGS]) and an incidence sample with 563 individuals (Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances [STRATA-G]).
Main Outcomes And Measures:
GWAS of treatment resistance in schizophrenia. The results of the GWAS were compared with complex polygenic traits through a genetic correlation approach and were used for PRS analysis on the independent validation cohorts using the same TRS definition.
Results:
The study included a total of 85 490 participants (48 635 [56.9%] male) in its GWAS stage and 1380 participants (859 [62.2%] male) in its PRS validation stage. Treatment resistance in schizophrenia emerged as a polygenic trait with detectable heritability (1% to 4%), and several traits related to intelligence and cognition were found to be genetically correlated with it (genetic correlation, 0.41-0.69). PRS analysis in the CardiffCOGS prevalence sample showed a positive association between TRS and a history of taking clozapine (r2 = 2.03%; P = .001), which was replicated in the STRATA-G incidence sample (r2 = 1.09%; P = .04).
Conclusions And Relevance:
In this GWAS, common genetic variants were differentially associated with TRS, and these associations may have been obscured through the amalgamation of large GWAS samples in previous studies of broadly defined schizophrenia. Findings of this study suggest the validity of meta-analytic approaches for studies on patient outcomes, including treatment resistance.
Insights
Treatment-resistant schizophrenia (TRS) has a polygenic architecture, with genetic links to intelligence and cognition. This study reveals genetic variants associated with TRS, aiding future research into patient outcomes.
Area of Science:
- Psychiatry
- Genetics
- Neuroscience
Background:
- Treatment-resistant schizophrenia (TRS) affects 20-30% of patients, presenting a significant clinical challenge.
- The genetic underpinnings of TRS remain largely unknown due to limited well-characterized cohorts.
- Understanding TRS genetics is crucial for developing targeted therapeutic strategies.
Purpose of the Study:
- To investigate the genetic architecture of treatment-resistant schizophrenia (TRS).
- To reassess existing genetic data from schizophrenia studies for TRS-specific associations.
- To validate findings in independent clinical samples.
Main Methods:
- Conducted two genome-wide association studies (GWAS) comparing individuals with TRS (n=10,501) and non-TRS (n=20,325).
- Analyzed allelic association effect size differences to identify TRS-specific genetic variants.
- Validated findings using polygenic risk score (PRS) profiling in two independent cohorts (CardiffCOGS and STRATA-G).
Main Results:
- Treatment resistance in schizophrenia was identified as a polygenic trait with 1-4% heritability.
- Significant genetic correlations were found between TRS and traits related to intelligence and cognition (correlation, 0.41-0.69).
- Polygenic risk score analysis indicated a positive association between TRS and clozapine use in both validation cohorts.
Conclusions:
- Common genetic variants are differentially associated with TRS, potentially masked in previous broad schizophrenia studies.
- Meta-analytic approaches are validated for studying patient outcomes, including treatment resistance.
- These findings advance the understanding of TRS genetics and inform future research directions.
More Related Videos
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
Published on: August 21, 2016
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Psychological and Sociocultural Causes of Schizophrenia
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Drug Therapy
Antianxiety Medications